Clinical Computing PLC
16 May 2002
For Immediate Release 16 May 2002
Clinical Computing Plc
Chairman's AGM Statement
Clinical Computing plc ('the Group'), the international developer of clinical
information systems for the healthcare market, held its AGM in Richmond, Surrey
at 12 noon today. All resolutions were passed.
At the AGM, Mike Gordon, Chairman, told shareholders:
'The Group's focus for the first half of this year has been the completion of
the Clinical Vision product. Clinical Vision Version 4.0 is now in the quality
assurance phase of the development life cycle. We plan to install it at our US
Beta site before the end of the first half 2002, and we will then implement the
backlog of orders. The initial specialty will be renal dialysis, followed
shortly thereafter by transplant products for kidney, liver, heart, lung, and
pancreas. The tools created with the Clinical Vision 4.0 framework position the
Group to build further applications efficiently and rapidly. Clinical Vision
4.0 matches the increased focus of the NHS on clinical systems that can
integrate to provide a total patient record.
Having guided the Group through the development of Clinical Vision for the past
few years, and now seeing its completion I propose to step aside for a younger
colleague, Howard Kitchner, a current non-executive, to succeed me as Chairman.
This will assist the Group's transition from product development to sales and
marketing. I will, however, stay involved with the company as a non-executive
director.
First half results for 2002 are expected to be similar to those of first half
2001. I remain confident about the prospects for Clinical Vision and for our
expansion in both current and broader markets.'
ENDS
Contacts:
Clinical Computing PLC Binns & Co PR Ltd
Jack Richardson, Chief Executive Paul McManus
Tel: 020 8380 4400 Tel: 07980 541893
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.